Genmab — Juni 2015
-
De presser på endnu anonyme (bluecrest)
-
Nu er du krævende Celsius

-
Bluecrest. Ring til dem og sig de skylder en forklaring
-
NICE har udsendt den officielle anbefaling af Ofatumumab med Chlorambucil eller Bendamustine: "Ofatumumab in combination with chlorambucil or
bendamustine has a marketing authorisation in the UK for treating chronic
lymphocytic leukaemia in people who have not had prior therapy and who are
not eligible for fludarabine-based therapy." -
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia | Guidance | NICE
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra)
(www.nice.org.uk)
-
Man siger jo at lykken er med de tossede. M.h.t. Gen er jeg nok tosset da jeg har suppleret hele vejen op. For nogle år siden solgte jeg også men det har jeg ikke gjort i siden bunden. Sværger normalt til en spredning på mellem 8 og 15 aktier. Har fortsat det antal - men efter øgning i dag til gns 91,5 har jeg nu over 30 pct i Genmab. Overvejer somme tider om jeg skal blive helt tosset og sætte alt i Gen
Det gør jeg nok ikke - men hold kæft hvor det føles godt med 30 pct når det går op :-).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind